Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3971297 in HFpEF and HFrEF
NCT07547540Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Primary completion
- Nov 2027
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 1, randomised, single-blind trial of LY-3971297 in heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) (12 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 2 months and Number of Participants with One or More Treatment-Emergent Adverse Event at 2 months. Started Aug 2026; status: recruiting.
02
Drugs
LY-3971297
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07547540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547540.